Alpha-mangostin and nab-paclitaxel in breast cancer cell models: improved antitumor efficacy through combination
Özge Özgen1, İdil Çetin2, Fatmahan Atalar3
1Aziz Sancar Institute of Experimental Medicine, Molecular Medicine Department, Istanbul University, Istanbul Turkiye. drozgozgen@gmail.com.
Abstract:
In the pursuit of more effective breast cancer therapies, the investigation of interactions between novel compounds and established chemotherapeutics has become increasingly important. This study investigates the combinatory effects of alpha-mangostin (α-MG) and nab-paclitaxel on MCF-7 and MDA-MB-231 cell lines, utilizing the xCELLigence RTCA system for continuous real-time cellular analysis, BrdU incorporation assays for proliferation assessment, and the quantification of mitotic activity and caspase-3/7 levels to elucidate apoptotic mechanisms. Our findings demonstrate that both α-MG and nab-paclitaxel independently induce significant inhibition of cellular proliferation and modulate cell cycle dynamics over a 24 to 72-hour period. Notably, when combined, these agents exhibit a pronounced enhancement of cell cycle inhibition and apoptosis, surpassing the effects observed with monotherapy. This potentiation effect suggests that α-MG augments the therapeutic efficacy of nab-paclitaxel, potentially allowing for reduced dosages in clinical applications. The study underscores the potential of α-MG as an adjuvant in breast cancer treatment, offering a promising strategy to optimize therapeutic regimens, minimize adverse effects, and improve patient outcomes in clinical oncology.
Insights
Alpha-mangostin (α-MG) combined with nab-paclitaxel significantly enhances breast cancer cell death and inhibits proliferation. This combination therapy shows promise for improving treatment efficacy and potentially reducing drug dosages in clinical settings.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Developing novel breast cancer therapies requires understanding interactions between new compounds and existing chemotherapeutics.
- Alpha-mangostin (α-MG) and nab-paclitaxel are key agents in breast cancer research and treatment.
Purpose of the Study:
- To investigate the combinatory effects of α-MG and nab-paclitaxel on breast cancer cell lines.
- To evaluate the impact of this combination on cellular proliferation, cell cycle, and apoptosis.
Main Methods:
- Utilized the xCELLigence RTCA system for real-time cellular analysis.
- Employed BrdU incorporation assays to assess proliferation.
- Quantified mitotic activity and caspase-3/7 levels to determine apoptotic mechanisms.
Main Results:
- Both α-MG and nab-paclitaxel demonstrated independent inhibition of proliferation and modulated cell cycle dynamics.
- The combination of α-MG and nab-paclitaxel synergistically enhanced cell cycle inhibition and apoptosis compared to monotherapy.
- Findings suggest α-MG potentiates the efficacy of nab-paclitaxel.
Conclusions:
- α-MG acts as an effective adjuvant to nab-paclitaxel in breast cancer treatment.
- This combination strategy may allow for reduced drug dosages, potentially minimizing adverse effects.
- The study highlights a promising approach to optimize breast cancer therapeutic regimens and improve patient outcomes.
More Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...